10-K: Day One Biopharma's OJEMDA Drives Revenue, Expands Oncology Pipeline

Day One Biopharmaceuticals reports significant revenue growth from its newly approved pediatric brain tumor therapy, OJEMDA, while strategically expanding its oncology pipeline through key acquisitions and licensing deals.

Summary

• Day One Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for life-threatening diseases across all ages.
• OJEMDA (tovorafenib), an oral, brain-penetrant RAF kinase inhibitor, received FDA accelerated approval on April 23, 2024, for relapsed or refractory pediatric low-grade glioma (pLGG) with BRAF fusions/rearrangements or V600 mutations.
• The company commenced commercial launch of OJEMDA in the United States, generating $155.4 million in net product revenue for the year ended December 31, 2025, a 171.6% increase from $57.2 million in 2024.
• Updated FIREFLY-1 trial data (June 6, 2025 cutoff) for OJEMDA in pLGG showed an overall response rate (ORR) of 53%, median duration of response of 19.4 months, and median time-to-next-treatment of 42.6 months, with no new safety signals.
• OJEMDA was added to the NCCN adult glioma treatment guidelines as a category 2a recommended option for recurrent or progressive BRAF-altered disease in June 2025.
• In July 2024, Day One licensed ex-U.S. commercialization rights for tovorafenib to Ipsen Pharma SAS, receiving an upfront license fee of $70.8 million and a $40.0 million equity investment from Ipsen Biopharmaceuticals, Inc. (at a 17.0% premium).
• The Ipsen agreement includes eligibility for up to $375.0 million in additional commercial launch and sales-based milestones, plus tiered, double-digit royalties starting at mid-teens percentage of annual net sales.
• Ipsen's Marketing Authorization Application for tovorafenib in relapsed or refractory pLGG was validated by the EMA on March 27, 2025, with a regulatory decision anticipated in 2026.
• Day One acquired Mersana Therapeutics, Inc. on January 6, 2026, for $25.00 per share in cash plus one contingent value right (CVR) per share, totaling up to $30.25 per CVR, adding Emiltatug ledadotin (Emi-Le) to its pipeline.
• Emi-Le, a B7-H4-directed ADC, is a potential first-in-class monotherapy for adenoid cystic carcinoma (ACC), with early anti-tumor activity observed in an ongoing Phase 1 study.
• In June 2024, Day One licensed DAY301, a PTK7-targeted ADC, from MabCare Therapeutics for exclusive worldwide rights (excluding Greater China), involving an upfront payment of $55.0 million and potential future payments of up to $1.132 billion in milestones plus low-to-mid single-digit royalties.
• The FDA cleared the IND for DAY301 in April 2024, and the first cohort of its Phase 1a/b clinical trial was cleared in January 2025.
• The company reported a net loss of $107.3 million for the year ended December 31, 2025, compared to $95.5 million in 2024, with an accumulated deficit of $661.4 million as of December 31, 2025.
• Cash, cash equivalents, and short-term investments totaled $441.1 million as of December 31, 2025.
• The pivotal Phase 3 FIREFLY-2 trial for tovorafenib as a front-line pLGG therapy is ongoing, with enrollment expected to complete in the first half of 2026.
• Day One discontinued its VRK1 inhibitor program (Sprint License Agreement terminated effective August 15, 2025) and its pimasertib program (Merck KGaA termination finalized September 2025) due to strategic considerations and benefit/risk profiles.
• The company sold its rare pediatric disease Priority Review Voucher (PRV) for $108.0 million in May 2024.
• As of February 19, 2026, 103,297,691 shares of common stock were outstanding.
• The company maintains product liability insurance and cybersecurity insurance, but coverage may not be sufficient for all potential liabilities.
• The company's internal control over financial reporting was effective as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by the successful commercial launch and robust clinical data for OJEMDA, coupled with strategic pipeline expansion through significant licensing deals and acquisitions. While net losses persist, the substantial revenue growth and non-dilutive funding demonstrate strong operational execution and future potential.

Positives

• OJEMDA (tovorafenib) received FDA accelerated approval on April 23, 2024, for relapsed or refractory pLGG, marking the company's first commercial product.
• Net product revenue for OJEMDA increased significantly to $155.4 million in 2025, up 171.6% from $57.2 million in 2024, demonstrating strong initial commercialization.
• Updated FIREFLY-1 trial data for OJEMDA showed a consistent overall response rate (ORR) of 53% and a median duration of response of 19.4 months, with no new safety signals, reinforcing its efficacy and durability.
• OJEMDA's inclusion in the NCCN adult glioma treatment guidelines as a category 2a recommended option in June 2025 enhances its market acceptance and physician adoption.
• The exclusive licensing agreement with Ipsen Pharma SAS for ex-U.S. commercialization of tovorafenib provides an upfront payment of $70.8 million, a $40.0 million equity investment, and potential milestones up to $375.0 million plus double-digit royalties, securing international market access and funding.
• The acquisition of Mersana Therapeutics, Inc. on January 6, 2026, adds Emiltatug ledadotin (Emi-Le), a potential first-in-class monotherapy for adenoid cystic carcinoma (ACC), expanding the oncology pipeline with a high unmet medical need asset.
• The FDA cleared the Investigational New Drug (IND) application for DAY301 in April 2024, and the first cohort of its Phase 1a/b trial was cleared in January 2025, advancing a novel PTK7-targeted ADC.
• The MabCare License Agreement for DAY301 includes an upfront payment of $55.0 million and potential future milestone payments of up to $1.132 billion, providing substantial non-dilutive funding for pipeline development.
• The company's cash, cash equivalents, and short-term investments of $441.1 million as of December 31, 2025, are estimated to be sufficient to satisfy capital requirements for at least twelve months.
• The sale of the rare pediatric disease Priority Review Voucher (PRV) for $108.0 million in May 2024 provided significant non-dilutive capital.

Negatives

• The company incurred a net loss of $107.3 million in 2025, following a $95.5 million net loss in 2024, and has an accumulated deficit of $661.4 million, indicating continued unprofitability.
• Near-term revenues are highly dependent on the successful commercialization of OJEMDA, and any failure to meet market expectations could significantly impact financial results and stock price.
• The company relies on a limited number of third-party manufacturers, some located in China, for active pharmaceutical ingredients (API) and drug product manufacturing, exposing it to supply chain disruptions, increased costs, and geopolitical risks.
• The discontinuation of the Sprint VRK1 inhibitor program and the Merck KGaA pimasertib program highlights the inherent risks and potential failures in drug development, leading to sunk costs.
• The biopharmaceutical industry is highly competitive, with many larger companies possessing greater financial resources and established market presence, posing a challenge to Day One's market share and profitability.
• The company has limited experience as a commercial company, and the successful establishment of sales, marketing, and distribution capabilities for OJEMDA and future products is uncertain and involves significant expenses and risks.
• The market opportunities for products targeting rare diseases like pLGG may be smaller than estimated, potentially limiting revenue generation even with market approval.
• The company faces substantial product liability risks inherent in the development and commercialization of therapeutic treatments, and current insurance coverage may not be sufficient.
• The company is subject to stringent and changing laws and regulations related to privacy, data protection, and data security, with potential for significant penalties and reputational harm for non-compliance.
• Disruptions at the FDA or other regulatory agencies, including staffing changes or government shutdowns, could delay product reviews and approvals, adversely affecting the business.

Risks

• Limited operating history and initial stages of commercialization for OJEMDA make it difficult for investors to evaluate current business and likelihood of success.
• Expectation of continued net losses for the foreseeable future and uncertainty of achieving or maintaining profitability.
• High dependence of near-term revenues on the successful commercialization of OJEMDA.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes, with results of earlier studies not always predictive of future trials.
• Reliance on data from investigator-initiated studies, where control over trial operations or reporting of results is limited.
• Development and commercialization of pharmaceutical products are subject to extensive regulation, and timely marketing authorizations for product candidates are not guaranteed.
• Complexity of pharmaceutical manufacturing and potential difficulties encountered by third-party manufacturers, leading to supply delays or halts.
• Future success depends on the ability to retain executive officers and key employees and to attract, retain, and motivate qualified personnel.
• Need to grow the size and capabilities of the organization, which may lead to difficulties in managing growth.
• Inability to obtain and maintain sufficiently broad patent protection or other necessary intellectual property rights, allowing competitors to commercialize similar products.
• Significant risk of product liability claims inherent in the development, testing, manufacturing, and commercialization of therapeutic treatments.
• Product candidates may not achieve adequate market acceptance among physicians, healthcare professionals, patients, or payors.
• Products may become subject to unfavorable third-party coverage and reimbursement practices, as well as price restrictions.
• Exposure to the risk of fraud or other misconduct by employees, clinical trial investigators, CROs, CMOs, consultants, vendors, and future commercial partners.
• Compromised security measures or failures in information technology systems (internal or third-party) could lead to data breaches, liability, and reputational harm.
• Subject to stringent and changing laws, regulations, standards, and contractual obligations related to privacy, data protection, and data security.
• Adverse effects from natural disasters or other disruptions, as current operations are primarily located in the San Francisco Bay Area.
• Changes in tax laws or regulations that are applied adversely, potentially impacting business, cash flow, financial condition, or results of operations.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to potential ownership changes.
• Strategic transactions could impact liquidity, increase expenses, and present significant distractions to management.
• Claims by third parties of infringement on their proprietary rights, potentially resulting in liability or delays in development and commercialization.
• Dependence on third-party license agreements, with risks of termination or narrow interpretation of rights.
• Involvement in lawsuits to protect or enforce patents, which could be expensive, time-consuming, and unsuccessful.
• Recent patent reform legislation could increase uncertainties and costs surrounding patent prosecution and enforcement.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Inadequate patent terms to protect competitive position for a sufficient amount of time.
• Inability to protect intellectual property rights throughout the world, especially in jurisdictions with less extensive protection.
• Unfavorable global economic conditions, including inflation, interest rate changes, and geopolitical conflicts, could adversely affect business and stock price.
• Increased costs as a result of operating as a public company, including compliance initiatives and corporate governance practices.
• Potential for securities litigation due to stock price volatility, leading to substantial costs and diversion of management attention.

Future Outlook

Day One Biopharmaceuticals expects to complete enrollment for its pivotal Phase 3 FIREFLY-2 trial for tovorafenib in front-line pLGG in the first half of 2026. Ipsen anticipates a regulatory decision for tovorafenib in relapsed or refractory pLGG from the EMA in 2026. The company plans to present initial clinical data and provide a program update for DAY301 in the second half of 2026, and clinical data for Emi-Le (from the Mersana acquisition) in mid-2026. The company anticipates continued significant operating losses for the foreseeable future as it advances its product candidates through clinical development and expands commercialization efforts.

Management Comments

• We aim to identify and develop breakthrough medicines with the goal of improving the outcomes and life trajectories of patients of any age facing serious diseases – starting from Day One.
• We believe our business development capabilities combined with our extensive experience in oncology drug development and deep ties within the research and patient advocacy communities, particularly within the pediatric setting, positions us to be a leader in identifying, acquiring and developing therapies for patients of all ages.
• We believe that tovorafenib has the potential to be a high-impact targeted therapeutic in pLGG, where over half of pLGGs are driven by abnormal signaling due to RAF alterations.
• We believe that treating patients before they have undergone multiple rounds of toxic chemotherapy has the potential to both improve the efficacy of tovorafenib and reduce the overall burden of therapy and related toxicities associated with the use of currently-employed cytotoxic agents.
• We believe that tovorafenib has the potential to provide long-term benefit – similar to effective therapies for more traditional chronic rare diseases – to patients with pLGG.
• We believe that Emi-Le is well positioned for potential rapid development and commercialization as a novel targeted investigational agent with monotherapy anti-tumor activity intended for a well-defined patient population without any approved therapies or a clear standard of care.
• We believe our cash, cash equivalents and short-term investments will be sufficient to satisfy our capital requirements at least twelve months after the date that this Annual Report is filed.

Industry Context

StockSavvy.ai notes that Day One Biopharmaceuticals is strategically positioning itself in the high-growth targeted oncology market, particularly in pediatric cancers, which often present favorable regulatory pathways due to unmet medical needs. The company's focus on RAF kinase inhibitors and Antibody Drug Conjugates (ADCs) aligns with current industry trends towards precision medicine. The acquisition of Mersana Therapeutics and the licensing of DAY301 demonstrate an aggressive pipeline expansion strategy, aiming to diversify beyond its lead product, OJEMDA. The discontinuation of the VRK1 and pimasertib programs reflects a disciplined approach to portfolio management, prioritizing assets with clearer clinical benefit and market opportunity. The Ipsen licensing deal for ex-U.S. rights to tovorafenib is a common strategy for smaller biotechs to leverage established global pharmaceutical companies for broader market penetration and non-dilutive funding, while retaining control over the lucrative U.S. market. The competitive landscape for BRAF and MEK inhibitors is intense, with several established and next-generation therapies in development, underscoring the importance of differentiated profiles and strong clinical data for market success.

Comparison to Industry Standards

• OJEMDA's overall response rate (ORR) of 53% and median duration of response (DoR) of 19.4 months in relapsed or refractory pLGG (FIREFLY-1 trial) are competitive, especially given the high unmet need and lack of consensual standard of care for the majority of pLGG patients.
• Compared to dabrafenib in combination with trametinib (Novartis), which received full approval for BRAF V600E pLGG in March 2023, OJEMDA offers a once-weekly monotherapy dosing regimen, potentially improving patient convenience and reducing side effects associated with combination therapies.
• The safety profile of OJEMDA, with the majority of adverse events being Grade 1 or Grade 2, appears favorable compared to traditional chemotherapy regimens, which often result in significant Grade 3 or 4 adverse events (e.g., vincristine/carboplatin for newly diagnosed pLGG showed >95% of patients experiencing Grade 3 or 4 adverse events).
• In the PTK7-targeted ADC space, DAY301 is entering a competitive field. Profound Bio's PRO1107 (later Genmab's GEN1107) was discontinued in September 2025 due to benefit-risk balance, suggesting challenges in this target. Sichuan Kelun Pharmaceutical Research Institute's SKB518 and Eli Lilly's LY4175408 are also in early-phase clinical trials, indicating a race to market for effective PTK7 ADCs.
• For adenoid cystic carcinoma (ACC), Emi-Le (from Mersana acquisition) is positioned in a disease with no approved systemic therapies. Competitors like puxitatug samrotecan (AZD8205), sacituzumab govitecan, and enfortumab vedotin are being studied in investigator-sponsored Phase 2 trials, highlighting the early stage of development for ACC treatments and Emi-Le's potential to be a first-in-class monotherapy.

Corporate Governance

Legal Proceedings

• The company is not subject to any material legal proceedings, and to the best of its knowledge, no material legal proceedings are currently pending or threatened.

Related Party Transactions

• Millennium Pharmaceuticals, Inc., an affiliate of Takeda Pharmaceutical Company Limited, was a related party in the Takeda Asset Agreement (December 16, 2019) and the Millennium Stock Exchange Agreement (May 26, 2021).
• Ipsen Biopharmaceuticals, Inc., a fully-owned affiliate of Ipsen Pharma SAS, purchased 2,341,495 shares of common stock for $40.0 million in a private placement as part of the Ipsen License Agreement (July 23, 2024).

Stakeholder Impact

• **Shareholders**: Potential for increased value from successful commercialization of OJEMDA and pipeline expansion, but also risk of dilution from future capital raises and stock price volatility. Concentrated ownership by principal stockholders and management could influence corporate actions.
• **Employees**: Continued growth in employee numbers and scope of operations, particularly in clinical development, manufacturing, regulatory affairs, sales, marketing, and distribution. Competitive compensation and benefits, including equity incentive plans, are used for attraction and retention. Option repricing aimed at retaining key contributors.
• **Customers (Patients & Physicians)**: Availability of OJEMDA as the only systemic, once-weekly therapy for relapsed or refractory pLGG, offering a new treatment option. Future product candidates like Emi-Le and DAY301 aim to address high unmet medical needs in other cancers. Companion diagnostics (FoundationOne CDx) facilitate patient identification.
• **Suppliers & Contract Manufacturers**: Continued reliance on third-party contract manufacturing organizations (CMOs) and a limited number of raw material suppliers, including some in China, introduces supply chain risks and potential cost increases due to tariffs or geopolitical events.
• **Creditors**: The company's ability to generate future revenue and achieve profitability will impact its creditworthiness and ability to service any future debt. Current liquidity is deemed sufficient for at least 12 months.

Next Steps

• Complete enrollment of the pivotal Phase 3 FIREFLY-2 trial for tovorafenib in front-line pLGG in the first half of 2026.
• Ipsen anticipates a regulatory decision from the EMA for tovorafenib in relapsed or refractory pLGG in 2026.
• Present initial clinical data and provide a program update for DAY301 in the second half of 2026.
• Present clinical data for Emi-Le (from Mersana acquisition) in mid-2026.
• Continue to commercialize OJEMDA in the United States and support Ipsen's commercialization efforts outside the U.S.
• Identify, acquire, and develop additional product candidates to further expand the targeted oncology pipeline.
• Monitor and comply with post-marketing requirements and commitments for OJEMDA.

Key Dates

Recommendation

Day One Biopharmaceuticals demonstrates strong momentum with the successful commercial launch of OJEMDA, which is generating significant revenue and has shown robust clinical data. The strategic expansion of its oncology pipeline through the Ipsen licensing deal and the Mersana acquisition adds promising assets with substantial market potential and non-dilutive funding. While the company is still incurring net losses, the clear path to market for OJEMDA and the advancement of new drug candidates in areas of high unmet medical need suggest strong long-term growth prospects. The disciplined approach to discontinuing less promising programs further strengthens the investment thesis.

Keywords

Biopharmaceuticals, Oncology, Pediatric Low-Grade Glioma, pLGG, BRAF Alterations, RAF Kinase Inhibitor, OJEMDA, Tovorafenib, Antibody Drug Conjugate, ADC, Emiltatug Ledadotin, Emi-Le, Adenoid Cystic Carcinoma, ACC, PTK7, DAY301, Clinical Trials, FDA Approval, Orphan Drug, Breakthrough Therapy, Rare Pediatric Disease, Licensing Agreement, Ipsen, MabCare, Mersana Acquisition, Drug Development, Commercialization, Biotechnology